Sign up for our eNews and discover more about what we're up to, the difference we're making, and, most importantly, how you can help.
- 75% of all dementia cases go undiagnosed across the globe, up to 90% in low-middle-income-countries
- Clinician stigma still a major barrier to diagnosis, with 1 in 3 believing nothing can be done
- 90% of clinicians identified additional diagnosis delays due to COVID-19
- Tsunami of demand for dementia diagnosis set to overwhelm healthcare systems as dementia drugs become available, and diagnosis testing is transformed
Australia, World Alzheimer’s Day, 21 September 2021: A new report has found that an estimated 41 million cases of dementia across the globe are undiagnosed. This, combined with new treatment breakthroughs could result in an oncoming ‘tsunami of demand’ for diagnosis, which could overwhelm unprepared healthcare systems in Australia, say Dementia Australia and Alzheimer’s Disease International (ADI), the global federation for over 100 Alzheimer’s and dementia associations across the world.
McGill University in Montreal, Canada was commissioned to deliver ADI’s annual World Alzheimer Report 2021 ‘Journey through the diagnosis of dementia’, which finds that 75 percent of 55 million people with dementia are not diagnosed worldwide. This figure is as high as 90 percent in lower-to-middle-income (LMIC) countries.
For the first time in decades, a new drug treatment for Alzheimer’s disease is on the market in the US, with the FDA conditionally approving aducanumab for use in early Alzheimer’s patient populations. Without a diagnosis many people living with dementia worldwide and in Australia may not be able to access new treatment breakthroughs.
Furthermore, blood biomarker testing for dementia diagnosis is expected to be available in the coming years, making diagnosis more accurate than ever before. McGill University Professor Emeritus and World Alzheimer Report author Serge Gauthier says these new diagnostic tools will increase pressure on healthcare systems to provide diagnoses.
“The emergence of quicker, easier, cheaper, less invasive blood biomarker diagnostic tools will combine with emerging drug treatments and the global ageing population to create a tsunami of demand for diagnosis putting extreme pressure on healthcare systems,” says Professor Gauthier.
“Now that for the first time in decades, an Alzheimer’s drug treatment targeting a key protein involved in the disease process is available in the US and may soon be available in other parts of the world, people will not be able to access them without an accurate diagnosis.”
According to the new World Health Organisation (WHO) statistics, dementia is the seventh leading cause of death among all diseases worldwide. Concerningly, stigma is still a major barrier to diagnosis, with the World Alzheimer Report survey revealing that one in three clinicians that nothing can be done, making diagnosis futile.
Paola Barbarino, ADI CEO, says that “lack of awareness and stigma within healthcare systems is hampering efforts to support people living with dementia".
“This misinformation in our healthcare systems, along with a lack of trained specialists and readily available diagnosis tools have contributed to alarmingly low diagnosis rates,” says Barbarino.
“We need healthcare systems across the globe to ensure that their national dementia plan includes specialist dementia training and adequate diagnostic equipment.”
“For over 20 years we have been calling on world governments to implement national dementia plans, and frankly, progress has been too slow,” says Barbarino.
“Now the tide has turned, and demand is set to skyrocket. Governments must respond now.”
The WHO global action plan on dementia stipulated that half of countries should be diagnosing 50 percent of the expected number of those living with dementia, however ADI data suggests that the diagnosis rates in Member States could be as low as 25 percent in higher income countries and 10 percent in lower-middle-income countries. Furthermore, 90 percent of clinicians identified additional delays and wait times for providing diagnosis due to the ongoing COVID-19 pandemic. Just one in three people with dementia and their caregivers have had in-person access to a clinician throughout the pandemic.
Dementia Australia Chair, Professor Graeme Samuel AC says obtaining a timely diagnosis of dementia is crucial because it enables a person with dementia to adjust to the diagnosis, access early support and treatment options and to prepare for the future in an appropriate way.
“This might include making legal and financial arrangements, changes to living arrangements, and finding out about treatment, supports and services that will enhance quality of life for people with dementia and their family and friends.
“Recent measures announced in the Australian Federal Budget 2021 are strongly focused on more consistent dementia pathways including better access to a timely diagnosis,” says Prof Samuel.
Nell Hawe who was diagnosed with younger onset dementia at age 52 says my diagnosis experience was harrowing.
“Experts were complacent and they wanted to brush it off and call it stress. I went for two years before someone would even listen. I felt frustrated that I wasn’t listened to despite knowing what I was experiencing was the early stages of dementia,” says Ms Hawe.
“I could have been on medication during that two years and I do wonder what interventions I could have had in this time. What services and supports did I miss out on? Are my symptoms worse because of the delay in my diagnosis?
“Two years is a long time when you have a degenerative, chronic disease with no cure.”
Three in four clinicians ranked the increasing number of people seeking a diagnosis, as global populations age, as a major challenge in the future, followed by people seeking diagnosis due to self-testing.
Barbarino says that this shows that it’s more important than ever for world governments to be planning appropriately for the oncoming dementia diagnosis demand.
“People with dementia have a right to know their diagnosis, so they can know what to do next,” says Barbarino.
“This is a progressive disease, and figures are growing every year. There is a perfect storm gathering on the horizon and governments all over the world should get to grips with it.”
For story ideas, interview requests and more information, please contact:
About Alzheimer’s Disease International (ADI)
ADI is the international federation of 105 Alzheimer associations and federations around the world, in official relations with the World Health Organization. ADI's vision is prevention, care and inclusion today, and cure tomorrow. ADI believes that the key to winning the fight against dementia lies in a unique combination of global solutions and local knowledge. ADI works locally, by empowering Alzheimer associations to promote and offer care and support for persons with dementia and their care partners, while working globally to focus attention on dementia and campaign for policy change.
For more information, please visit www.alzint.org
World Alzheimer’s Month materials
Description of World Alzheimer’s Month:
September is World Alzheimer’s Month, an international campaign to raise dementia awareness and challenge stigma. Each year, Alzheimer and dementia associations, alongside all those involved in the treatment, care and support of people with dementia, from around the world unite to organise advocacy and information provision events, as well as Memory Walks and fundraising days.
Social media hashtags:
#WorldAlzMonth #KnowAlzheimers #KnowDementia
Images, infographics, headshots:
More media releases
Dementia Australia statement
Dementia Australia is devastated by the tragic events that have led to Ms Clare Nowland being hospitalised. We acknowledge the seriousness of her condition and extend our sincere sympathies to Ms Nowland and her family.
Welcome investment to support health and aged care in the Federal Budget
Dementia Australia welcomes the significant investment in the aged care workforce and dementia specific initiatives announced tonight in the Federal Budget including a Clinical Quality Registry, investment in rarer forms of dementia and funding for longer GP consultations, which will benefit people living with dementia, their families and carers.
Internationally renowned expert appointed inaugural Chair of Dementia
Curtin University and Dementia Australia are pleased to announce the appointment of the inaugural Chair of Dementia, Professor Blossom Stephan. Dementia is the second-leading cause of death among Australians, and the leading cause of death of women. It is also the leading cause of disease burden among Australians aged 65 and over.